The FDA has approved a new drug for patients with ALK-positive lung cancer. The drug is called brigatinib (brand name: Alunbrig) and is approved for treatment of patients whose tumor has the ALK mutation. Brigatinib is to be used after another drug targeting ALK stops working. The FDA press release is here: fda.gov/Drugs/InformationOn.... This is great news as it gives patients with the ALK mutation another treatment option.
A new drug for ALK-positive lung cance... - Lung Cancer Support
A new drug for ALK-positive lung cancer approved today
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
5 Replies
•
DenzieModeratorVolunteer
This is the 8th new treatment approved in the last 2 years. It's an exciting time to be an advocate.
This is terrific news!!! Thanks for sharing!
Keep the good news coming, Mary!
I live in Colorado. What about medical marijuana. I have stage4 lung cancer and am seeing my dr today
Not what you're looking for?
You may also like...
Opdivo and Yervoy combination approved for Non-small cell lung cancer
immunotherapy treatment for NSCLC. This gives patients whose cancer does not have a targetable...
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
the full FDA press release:...
New drug approved for patients with MET mutation.
rs/progress-against-cancer/targeting-non-small-cell-lung-cancer/
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
full release here: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezo
Adenocarcinoma lung cancer
hi my mum has just been diagnosed with possible stage3-4 Adenocarcinoma if the right lung and her...